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1. BRIEF REPORT {#mgg3521-sec-0005}
===============

Bardet‐Biedl syndrome (BBS:MIM209900) is a complex disease characterized mainly by severe photoreceptor degeneration, truncal obesity, postaxial polydactyly, autism‐like behavior, cognitive impairment, hypogonadism, renal anomalies, among other secondary features (Gerth, Zawadzki, Werner, & Heon, [2008](#mgg3521-bib-0016){ref-type="ref"}; Habibullah & Mohiuddin, [2009](#mgg3521-bib-0017){ref-type="ref"}; Heon et al., [2005](#mgg3521-bib-0019){ref-type="ref"}; Kerr, Bhan, & Heon, [2015](#mgg3521-bib-0022){ref-type="ref"}; Weihbrecht et al., [2017](#mgg3521-bib-0034){ref-type="ref"}). BBS is phenotypically and genetically heterogeneous, and demonstrates considerable overlap with other ciliopathies such as Joubert syndrome (JBST) (Beales, Elcioglu, Woolf, Parker, & Flinter, [1999](#mgg3521-bib-0002){ref-type="ref"}; Billingsley et al., [2010](#mgg3521-bib-0005){ref-type="ref"}; Branfield Day et al., [2015](#mgg3521-bib-0006){ref-type="ref"}; Deveault et al., [2011](#mgg3521-bib-0010){ref-type="ref"}; Gerth et al., [2008](#mgg3521-bib-0016){ref-type="ref"}; Heon et al., [2016](#mgg3521-bib-0018){ref-type="ref"}; Kerr et al., [2015](#mgg3521-bib-0022){ref-type="ref"}). Biallelic mutations have been identified in at least 21 BBS genes (Heon et al., [2016](#mgg3521-bib-0018){ref-type="ref"}; Khan et al., [2016](#mgg3521-bib-0023){ref-type="ref"}), all of which are involved in primary cilia structure and/or function (Alvarez‐Satta, Castro‐Sanchez, & Valverde, [2017](#mgg3521-bib-0001){ref-type="ref"}; Khan et al., [2016](#mgg3521-bib-0023){ref-type="ref"}). Approximately 80% of the clinically examined BBS cases (Forsythe & Beales, [2015](#mgg3521-bib-0013){ref-type="ref"}) have been associated with biallelic mutations in one of the 21 BBS genes, of which Bardet‐Biedl syndrome‐1 gene (*BBS1:*209,901) is the most frequently mutated (Billingsley, Deveault, & Heon, [2011](#mgg3521-bib-0004){ref-type="ref"}). Currently, reported mutations in BBS are as follows: missense, nonsense, frameshift, and nonframeshift variants; copy number variation; alternative splicing; and a few descriptions of complex rearrangements (Billingsley et al., [2011](#mgg3521-bib-0004){ref-type="ref"}; Khan et al., [2016](#mgg3521-bib-0023){ref-type="ref"}; Weihbrecht et al., [2017](#mgg3521-bib-0034){ref-type="ref"}). In this study, we report a novel exonic retrotransposon insertion into *BBS1*, which represents a new type of mutational event for BBS patients and may play a role in the missing heritability of this condition. This study was approved by the Research Ethic Board of the Hospital for Sick Children and met the Tenets of the Declaration of Helsinki.

The proband was a female from a sibship of three, born to nonconsanguineous parents of European origin (Figure [1](#mgg3521-fig-0001){ref-type="fig"}a). She presented with night blindness, constriction of visual field, and photophobia at the age of nine (Table [1](#mgg3521-tbl-0001){ref-type="table"}). Distance visual acuity was reduced (right: 20/400, left: 20/600), and severe generalized rod and cone photoreceptor degeneration was documented on an electroretinogram (ERG) (Supporting information Figure [S1](#mgg3521-sup-0001){ref-type="supplementary-material"}). This correlated with the observed retinal structural changes (macular atrophic changes and pigmentary retinal changes and vessel attenuation; Figure [1](#mgg3521-fig-0001){ref-type="fig"}b,c). It was not possible to perform a visual field test due to the developmental delay. However, based on the small residual central island of photoreceptors documented by optical coherence tomography (OCT), it is likely that the fields were very constricted (Figure [1](#mgg3521-fig-0001){ref-type="fig"}c). Other features included obesity (BMI 37.6 at 13 years old), postaxial polydactyly, fatty infiltration of the liver, elevated lipids, autism, and absence‐type seizures (Table [1](#mgg3521-tbl-0001){ref-type="table"}). The clinical phenotype was consistent with BBS (Beales et al., [1999](#mgg3521-bib-0002){ref-type="ref"}; Daniels et al., [2012](#mgg3521-bib-0009){ref-type="ref"}) and part of the phenotype variability associated with *BBS1* mutations (Deveault et al., [2011](#mgg3521-bib-0010){ref-type="ref"}).

![(a) Pedigree of the affected family and *BBS1* variant segregation; (b) retinal photography of the right eye centered on the optic nerve (ON, left image) and on the nasal retina (right image). Gray arrow locates the foveal area which shows atrophy (center of the retina), and a blunted reflex. Filled white arrow (right) points toward narrowed (very thin) vessels, p: bone spiculing pigmentary deposits typical of retinal degeneration. (c) Optical coherence tomography (OCT) of the right eye centered on the fovea (gray arrow) shows markedly disruption of outer retinal layers including the photoreceptor outer and inner segments, and the outer nuclear layer. rnfl: retinal nerve fiber layer, c: choroidal layer. Insert to the right shows the area scanned (green line). The quality of the images was limited due to the patient\'s ability to participate](MGG3-7-na-g001){#mgg3521-fig-0001}

###### 

Phenotype summary of the proband

  Onset symptoms                                                Age 9--10 years (nyctalopia, visual field constriction)
  ------------------------------------------------------------- -------------------------------------------------------------
  VA (14 years)                                                 20/400 (right eye), 20/600 (left eye)
  Anterior segment                                              Normal
  Retinal exam (15 years)                                       Macular atrophy, vessel attenuation, bone spiculing changes
  ERG amplitude (1 years)                                       Severe rod‐cone dystrophy
  Neurological findings (age 13 years)                          Absent Seizures, autism
  Normal Brain MRI                                              
  Head circumference: 57 cm                                     
  Kidney (age 13 years)                                         Normal structure and function
  Liver (age 13 years)                                          Fatty Infiltration, normal transaminases
  Lipids[a](#mgg3521-note-0002){ref-type="fn"} (age 13 years)   Cholesterol 6.4 mmol/L (⇑)
  Triglyceride 8.63 mmol/L (⇑)                                  
  Heart                                                         Situs Solitus, levocardia
  Spleen                                                        Mild splenomegaly
  Digits                                                        Postaxial polydactyly × 3 limbs
  Weight                                                        BMI 38.9
  Menarche                                                      13 years
  Developmental                                                 Delayed
  Other                                                         Recurrent ear infections, strabismus

Normal lipid values; cholesterol: 0.65--2.5 mmol/L, triglyceride: 0.40--103 mmol/L.

John Wiley & Sons, Ltd

Genetic testing initially done using a CLIA‐approved laboratory performing next‐generation sequencing on 19 BBS genes revealed a heterozygous *BBS1*(NM_024649.4) variant: c.1169 T\>G, p.Met390Arg, the most common mutation in *BBS1*. Segregation analysis of the variant by Sanger sequencing confirmed that the mutation was heterozygous in the proband and that the mother was a carrier. No other potentially pathogenic mutation was found in *BBS1* or other BBS‐associated genes. No significant copy number variation (CNV) was detected by microarray analysis.

Whole genome sequencing (WGS) was performed, and single‐nucleotide variants (SNVs), insertions/deletions (indels), and CNVs were annotated with our standard in‐house variant filtration pipeline approach (Supporting information Data [S1](#mgg3521-sup-0006){ref-type="supplementary-material"} and Figure [S2](#mgg3521-sup-0002){ref-type="supplementary-material"}). The five genes with biallelic variants (three genes with homozygous variants and two genes with compound heterozygous variants) were excluded because these were either platform based errors (*ZFPM1*, *SLCA6*), inframe deletion in a polymorphic region (*UBXN11*), or the variants did not segregate with the disease phenotype (*DNAH8, IGSF3*) (Supporting information Figure [S2](#mgg3521-sup-0002){ref-type="supplementary-material"}). Since BBS best fits the proband\'s phenotype, a CNV analysis was performed for *BBS1*(for which a heterozygous missense mutation was previously identified; Met390Arg)*,* and for two other ciliopathy‐related genes (for which heterozygous variants were also identified in the proband\'s WGS filtering (Supporting information Figure [S2](#mgg3521-sup-0002){ref-type="supplementary-material"}): *NPHP4* (NM_015102:exon26:c.3644+1G\>C), *CEP78* (NM_032171:exon15:c.1801--1G\>C)). CNV was not detected for any of the three genes (Supporting information Data [S1](#mgg3521-sup-0006){ref-type="supplementary-material"}, Figure [S2](#mgg3521-sup-0002){ref-type="supplementary-material"}), but during the visualization of the binary alignment map (BAM) for these three genes, we identified discrepant reads (split reads) in exon 13 of *BBS1*only (Figure [2](#mgg3521-fig-0002){ref-type="fig"}a). The split portion of the forward reads (127 bp) was 98.5% identical to a retrotransposon of the category SINE/VNTR/*Alu*subtype *F* (SVAF) in RepeatMasker (<http://www.repeatmasker.org>). This novel transposable element (TE) insertion on *BBS1* had not yet been reported in the database of retrotransposon insertion polymorphisms dbRIP (<http://dbrip.brocku.ca/searchRIP.html>). The corresponding mate pairs of the split reads were mapped at different parts of the human genome (hg19) where TEs of the similar category had been mapped. The TE insertion (*BBS1*:NM_02649.4:c.1214--1215ins (1700_1800);1198_1214) was validated using PCR and Sanger sequencing and verified to be paternally inherited (Figure [2](#mgg3521-fig-0002){ref-type="fig"}b,c, Supporting information Data [S1](#mgg3521-sup-0006){ref-type="supplementary-material"}, Figure [S3](#mgg3521-sup-0003){ref-type="supplementary-material"}, Table [S1](#mgg3521-sup-0005){ref-type="supplementary-material"}). The final sequence (GenBank MH395756, Supporting information Data [S2](#mgg3521-sup-0007){ref-type="supplementary-material"}) had higher similarity (95%--97.7%) with multiple SVA types B, D, and mostly F from the human whole genome sequence (hg19 in UCSC---<https://genome.ucsc.edu/>‐ using RepeatMasker track). The allele carrying the SVA insertion was expressed in patient‐derived lymphoblast cell line; these results showed that BBS1 protein is translated up to AA residue 406, followed by insertion of 46 new AA residues (corresponding to the SVA) before reaching stop codon (Supporting information Figure [S4](#mgg3521-sup-0004){ref-type="supplementary-material"}).

![Disease‐causing mutations in the proband with retrotransposon insertion detail. Pathogenic mutations are represented in purple, Target Site Duplication (TSD) is shown in cyan, and exon is represented in blue. (a) Schematic representation of the retrotransposon insertion in exon 13 of *BBS1* in Integrative Genome Viewer using the whole exome and the whole genome sequence alignment maps, respectively (Robinson et al., [2011](#mgg3521-bib-0028){ref-type="ref"}). Nucleotides matching the reference are gray; unmatched A, T, C, and G nucleotides to reference are color coded in green, red, blue, and orange, respectively. (b) Schematic diagram of the two alleles comprising both *BBS1* mutations (Met390Arg and the exonic TE insertion in exon 13) observed in the proband and parents. (c) Detailed characterization of the novel SVAF insertion detected in this study and schematic representation of the results used to assemble the mutation map. Each PCR product is represented as a bar overlapping the region they comprise in the mutation map. Chromatograms from Sanger sequencing represent the *BBS1*‐SVAF junction](MGG3-7-na-g002){#mgg3521-fig-0002}

The shorter PCR segment amplification (Supporting information Data [S1](#mgg3521-sup-0006){ref-type="supplementary-material"}, Figure [S3](#mgg3521-sup-0003){ref-type="supplementary-material"}) did not identify this particular SVA insertion in our cohort of 24 genetically unsolved BBS probands. Additionally, the insertion was not found in 2,504 control individuals from 1,000 genomes phase three databases, for which MELT, an automatic TE detection method was applied (Gardner et al., [2017](#mgg3521-bib-0015){ref-type="ref"}; Rishishwar, Tellez Villa, & Jordan, [2015](#mgg3521-bib-0027){ref-type="ref"}).

We validated our finding using Mobster (Thung et al., [2014](#mgg3521-bib-0032){ref-type="ref"}), an algorithm designed to detect transposable element insertions from next‐generation sequencing data (Supporting information Data [S1](#mgg3521-sup-0006){ref-type="supplementary-material"}). We then applied this method to five of unsolved BBS probands for which WGS data were available. However, no potentially disease‐causing TEs were identified for them.

We could not automatically detect the SVA insertion from the whole exome sequencing (WES) of the proband using the same protocols applied to WGS, mostly due to the lower number of reads bearing the *BBS1* and SVA junction in WES. However, some of those split reads can be observed in the WES reads map (Figure [2](#mgg3521-fig-0002){ref-type="fig"}a).

2. DISCUSSION {#mgg3521-sec-0006}
=============

We report for the first time an SVA retrotransposon insertion in a *BBS1*exon as a disease‐causing mechanism for BBS.

DNA transposable elements (TE) are mobile DNA elements that occupy nearly half of the human Genome (<http://genome.ucsc.edu>), yet are poorly explored (Kazazian & Moran, [2017](#mgg3521-bib-0021){ref-type="ref"}). The aggregate length of these sequences is 40 times greater than protein‐coding exons (Kazazian & Moran, [2017](#mgg3521-bib-0021){ref-type="ref"}; Lander et al., [2001](#mgg3521-bib-0024){ref-type="ref"}; Mills, Bennett, Iskow, & Devine, [2007](#mgg3521-bib-0026){ref-type="ref"}). Active TEs account for around 0.02% of the human genome and belong to the retrotransposon class (Kaer & Speek, [2013](#mgg3521-bib-0020){ref-type="ref"}; Lander et al., [2001](#mgg3521-bib-0024){ref-type="ref"}). Retrotransposons can be transcribed into RNA, reverse transcribed into cDNA, which is then reinserted in the genome at a new location (Kaer & Speek, [2013](#mgg3521-bib-0020){ref-type="ref"}; Lander et al., [2001](#mgg3521-bib-0024){ref-type="ref"}). It is estimated that one de novo insertion happens every 10--100 live births. The most abundant retrotransposon in the human genome is the Long Interspersed Nuclear Element (LINE; 17%), followed by Alu (11%) and composite SVA repeats (0.2%) (Kaer & Speek, [2013](#mgg3521-bib-0020){ref-type="ref"}; Lander et al., [2001](#mgg3521-bib-0024){ref-type="ref"}; Solyom & Kazazian, [2012](#mgg3521-bib-0029){ref-type="ref"}).

The role of transposable elements in disease has only been minimally explored. However, these can be pathogenic by inserting themselves into coding or regulatory portions of genes, facilitating chromosomal rearrangements, duplications, and deletions, among other mechanisms (Mills et al., [2007](#mgg3521-bib-0026){ref-type="ref"}). Only a few cases of human retinal degeneration have been reported to be caused by inserted retrotransposons; an *Alu* insertion on exon 9 of *MAK*, and intronic *Alu* insertion in *OPA1* (Bujakowska, White, Place, Consugar, & Comander, [2015](#mgg3521-bib-0007){ref-type="ref"}; Gallus et al., [2010](#mgg3521-bib-0014){ref-type="ref"}; Tucker et al., [2011](#mgg3521-bib-0033){ref-type="ref"}). A few cases have also been reported in animals; an L1 insertion in rodent *Nr2e3* (Chen, Rattner, & Nathans, [2006](#mgg3521-bib-0008){ref-type="ref"}), an intronic SINE insertion in canine *FAM161A* (Downs & Mellersh, [2014](#mgg3521-bib-0011){ref-type="ref"}), and an intronic insertion in equine *TRPM1* (Bellone et al., [2013](#mgg3521-bib-0003){ref-type="ref"}). Recently, two cases affected with nonBBS ciliopathy phenotypes were associated with retrotransposon insertions; a L1 in exon 7 of *CC2D2A*and an *Alu* in exon 16 of *ALMS1* (Takenouchi et al., [2017](#mgg3521-bib-0030){ref-type="ref"}; Taschner et al., [2016](#mgg3521-bib-0031){ref-type="ref"}). A recent study of BBS cases also found that 40% (6 out of 15) of the CNV deletions detected in their cohort (in *BBS1*, *BBS4*, *BBS5*, and *IFT74*) were mediated by *Alu*--*Alu* recombination (Lindstrand et al., [2016](#mgg3521-bib-0025){ref-type="ref"}).

The high amount of active TE in the human genome, and the technical difficulties associated with their detection suggests that they are likely an underexplored category of disease‐causing mutational events. Therefore, the implementation of TE detection protocols in the standard pipeline for search of disease‐causing variants can significantly increase diagnostic yield and improve patient care. Traditional methods such as candidate gene sequence and microarray analysis are unsuitable to capture large insertions such as TEs. Large‐scale sequence analysis such as whole exome and whole genome sequencing allows identification of TEs but require specific algorithms for automatic detection (Ewing, [2015](#mgg3521-bib-0012){ref-type="ref"}; Gardner et al., [2017](#mgg3521-bib-0015){ref-type="ref"}; Thung et al., [2014](#mgg3521-bib-0032){ref-type="ref"}), which are not systematically incorporated in the current practice (Takenouchi et al., [2017](#mgg3521-bib-0030){ref-type="ref"}). The WES is less efficient to WGS in automatic TE detection because some of the genomic segments including the junction between the gene of interest and inserted TE are eliminated at the exome capture step (Tucker et al., [2011](#mgg3521-bib-0033){ref-type="ref"}). Therefore, standard implementation of Mobster or other TE detection methods should be planned forward for WGS data. Currently, there is only one "population frequency database" of nonreference TEs insertions available, making it difficult to determine the prevalence of this mutational event in disease or in the general population (Gardner et al., [2017](#mgg3521-bib-0015){ref-type="ref"}; Rishishwar et al., [2015](#mgg3521-bib-0027){ref-type="ref"}). The incorporation of TE insertion frequencies from the 1,000 genomes, and other additional population databases, will allow for more efficient identification of potentially pathogenic TEs. Further larger‐scale implementation of such detection methods will allow for the discovery of more disease‐causing variants and provide a clearer idea of the role of TEs in the population and disease processes.
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